RenovoRx Showcases Promising Pharmacokinetic Data at ASCO GI 2025
Introduction to RenovoRx and Its Innovative TAMP™ Therapy RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company dedicated to revolutionizing oncology treatment, recently shared compelling data from its novel therapeutic platform at the ASCO Gastrointestinal Cancers Symposium…
Senior Care Partners (PACE) Enhances Elderly Patient Safety with DoseMeRx
Senior Care Partners (PACE) Enhances Elderly Patient Safety with DoseMeRx DoseMeRx Empowers Senior Care Partners (PACE) to Improve Elderly Patient Safety with Modernized Vancomycin Dosing DoseMe, a recognized leader in model-informed precision dosing (MIPD), has announced that Senior Care Partners…
VSee Health Secures $870K Deal with National Mental Health Firm
VSee Health, Inc. (Nasdaq: VSEE), a prominent leader in digital health services and customized telehealth workflows, recently announced the renewal of a contract valued at approximately $870,000 with a nationwide provider of mental and behavioral healthcare services. This renewal highlights…
Imperative Care Gains FDA Clearance for Zoom Stroke Treatment System
Imperative Care, Inc. has announced that its Zoom System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone marks the first comprehensive stroke thrombectomy system to feature large-bore .088” catheters designed for both access and…
Natera Reports Positive Phase III Trial Results in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, has unveiled groundbreaking new data from the Phase III CALGB (Alliance) / SWOG 80702 study. These findings were presented as a late-breaking oral presentation on January 25,…
Bristol Myers Squibb Presents CheckMate-8HW Results: Opdivo® Plus Yervoy® vs. Opdivo Monotherapy
Bristol Myers Squibb Presents Results from CheckMate-8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in MSI-H/dMMR Metastatic Colorectal Cancer Bristol Myers Squibb (NYSE: BMY) has announced results from an analysis of the three-arm Phase 3 CheckMate-8HW…
Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025
Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025 Exelixis Announces Promising Results from Phase 1b/2 STELLAR-001 Trial for Zanzalintinib in Metastatic Colorectal Cancer at ASCO GI 2025 Exelixis, Inc. (Nasdaq: EXEL) recently presented data…
Merck and Eisai Update on LEAP-015 Trial in Gastroesophageal Cancer
Merck and Eisai Update on LEAP-015 Trial in Gastroesophageal Cancer Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Eisai have shared results from the Phase 3 LEAP-015 trial, which evaluated the combination of KEYTRUDA® (pembrolizumab),…
Patients Benefit from GHLF’s Launch of Interactive Guide for Hidradenitis Suppurativa
Patients Benefit from GHLF’s Launch of Interactive Guide for Hidradenitis Suppurativa The Global Healthy Living Foundation (GHLF) has unveiled a new resource aimed at supporting those living with Hidradenitis Suppurativa (HS). The “Interactive Patient Guide to Hidradenitis Suppurativa” is designed…
Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium
Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium Parabilis Medicines, formerly known as Fog Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing transformative treatments for cancer patients, today announced that it will present…
Clinical Data Registry: McKesson’s Practice Insights Named 2025 QCDR by CMS
Clinical Data Registry: McKesson’s Practice Insights Named 2025 QCDR by CMS For the ninth year in a row, McKesson has been named a Qualified Clinical Data Registry (QCDR) by the Centers for Medicare & Medicaid Services (CMS), securing approval to…
Verastem Oncology Unveils Bold 2025 Priorities for RAS/MAPK Pathway Cancer Pipeline
Verastem Oncology Unveils Bold 2025 Priorities for RAS/MAPK Pathway Cancer Pipeline Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new treatments for RAS/MAPK pathway-driven cancers, has outlined its strategic priorities for 2025, as well as the key milestones…